Skip to main content
Livermore
Livermore
US stocksTW
ZHEN

Balyasny Asset Management LLC

SEC CIK
0001218710
Latest filing
Aug 14, 2026

The latest 13F from Balyasny Asset Management LLC covers Q2 2026 (filed Aug 14, 2026): 2,094 long positions worth $54.7B. The top 10 holdings make up 10.6% of the portfolio, and the largest is Amazon Com Inc (AMZN) at 2.1%. Livermore has 23 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Full comparison

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

New
607
Est. +$7.01B
Added
701
Est. +$17.6B
Reduced
717
Est. −$19.7B
Sold out
591
Est. −$7.23B

Top 5 holdings

Share of this quarter's portfolio value

  1. AMZNAmazon Com Inc
    2.1%$1.14BHistory
  2. NVDANVIDIA Corp
    1.2%$647.8MHistory
  3. SPYSPDR S&P 500 ETF Trust
    1.2%$643.5MHistory
  4. SPCXSpace Exploration Technologies Corp
    1.1%$580.5MHistory
  5. iShares Core S&P 500 ETF464287200
    1.0%$532.1M

Share of portfolio

Top 5 holdings and the other 2,089 positions, by share of portfolio value

  1. AMZN2.1%
  2. NVDA1.2%
  3. SPY1.2%
  4. SPCX1.1%
  5. iShares Core S&P 500 ETF1.0%
  6. Other 2,089 positions93.5%

Biggest buys

New and added positions, by estimated amount bought

  1. SPCXSpace Exploration Technologies Corp
    +$580.5MNewHistory
  2. SPYSPDR S&P 500 ETF Trust
    +$554.0MAddedHistory
  3. iShares Core S&P 500 ETF464287200
    +$532.1MNew
  4. TXNTexas Instruments Inc
    +$443.3MAddedHistory
  5. ROKURoku, Inc
    +$403.3MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. SPCXSpace Exploration Technologies Corp
    +1.06 pp0.0% → 1.1%History
  2. SPYSPDR S&P 500 ETF Trust
    +1.02 pp0.2% → 1.2%History
  3. iShares Core S&P 500 ETF464287200
    +0.97 pp0.0% → 1.0%
  4. TXNTexas Instruments Inc
    +0.81 pp<0.1% → 0.8%History
  5. ROKURoku, Inc
    +0.75 pp<0.1% → 0.8%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. Lumentum Hldgs Inc55024UAF6
    −$547.4MSold out
  2. AMATApplied Materials Inc
    −$446.1MReducedHistory
  3. HOLXHologic Inc
    −$357.0MSold outHistory
  4. ARMArm Holdings PLC
    −$323.3MReducedHistory
  5. Lumentum Hldgs Inc55024UAD1
    −$315.3MSold out

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. Lumentum Hldgs Inc55024UAF6
    −1.08 pp1.1% → 0.0%
  2. HOLXHologic Inc
    −0.70 pp0.7% → 0.0%History
  3. METAMeta Platforms, Inc.
    −0.66 pp1.3% → 0.7%History
  4. Lumentum Hldgs Inc55024UAD1
    −0.62 pp0.6% → 0.0%
  5. JCIJohnson Controls International plc
    −0.59 pp0.6% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$54.7B
+$3.78B (+7.4%) vs. prior quarter
Positions
2,094
+16 vs. prior quarter
Top 10 concentration
10.6%
Top 10 as share of value
Turnover
46.6%
Q2 2026, one quarter
Average holding period
7.9 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $54.7B (Q2 2026)

Q1 2021: $16.6BQ2 2021: $18.2BQ3 2021: $20.9BQ4 2021: $23.5BQ1 2022: $22.7BQ2 2022: $23.8BQ3 2022: $25.8BQ4 2022: $28.3BQ1 2023: $30.5BQ2 2023: $35.8BQ3 2023: $35.7BQ4 2023: $36.1BQ1 2024: $39.0BQ2 2024: $38.7BQ3 2024: $38.9BQ4 2024: $43.0BQ1 2025: $39.9BQ2 2025: $44.0BQ3 2025: $49.6BQ4 2025: $53.4BQ1 2026: $50.9BQ2 2026: $54.7B
Q1 2021Q2 2026
13F filings of Balyasny Asset Management LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 20262,094$54.7BAMZNNVDASPYvs. Q1 2026SEC
Q1 2026May 15, 20262,078$50.9BAMZNNVDAWBDvs. Q4 2025SEC
Q4 2025Feb 17, 20262,133$53.4BAMZNiShares Core S&P 500 ETFNVDAvs. Q3 2025SEC
Q3 2025Nov 14, 20251,941$49.6BiShares Core S&P 500 ETFMSFTNVDAvs. Q2 2025SEC
Q2 2025Aug 14, 20251,936$44.0BNVDAAMZNBROvs. Q1 2025SEC
Q1 2025May 15, 20251,952$39.9BSPYAMZNiShares Core S&P 500 ETFvs. Q4 2024SEC
Q4 2024Feb 14, 20251,871$43.0BAMZNTSMCRMvs. Q3 2024SEC
Q3 2024Nov 14, 20241,901$38.9BMSFTiShares Core S&P Mid-Cap ETFHESvs. Q2 2024SEC
Q2 2024Aug 14, 20241,863$38.7BiShares Core S&P Mid-Cap ETFAAPLAMZNvs. Q1 2024SEC
Q1 2024May 13, 20241,933$39.0BPXDiShares Core S&P Mid-Cap ETFAMZNvs. Q4 2023SEC
Q4 2023Feb 14, 20241,858$36.1BInvesco Exchange Traded FD THESiShares Russell 2000 ETFvs. Q3 2023SEC
Q3 2023Nov 14, 20231,716$35.7BiShares Russell 2000 ETFATVISPYvs. Q2 2023SEC
Q2 2023Aug 14, 20231,814$35.8BiShares Russell 2000 ETFAMZNMSFTvs. Q1 2023SEC
Q1 2023May 15, 20232,134$30.5BSPYiShares Russell 2000 ETFNVDAvs. Q4 2022SEC
Q4 2022Feb 14, 20232,281$28.3BSPYiShares Russell 2000 ETFPHMvs. Q3 2022SEC
Q3 2022Nov 15, 20222,316$25.8BSPYZENETNvs. Q2 2022SEC
Q2 2022Aug 15, 20222,239$23.8BSPYiShares Russell 2000 ETFRTXvs. Q1 2022SEC
Q1 2022May 16, 20222,067$22.7BSPYNSCHONvs. Q4 2021SEC
Q4 2021Feb 14, 20221,933$23.5BSPYINFOMSFTvs. Q3 2021SEC
Q3 2021Dec 1, 2021Amended1,615$20.9BSPYNUANGSvs. Q2 2021SEC
Q2 2021Aug 16, 20211,626$18.2BNUANINFOXLNXvs. Q1 2021SEC
Q1 2021May 17, 20211,520$16.6BMXIMWFCBAC–SEC

13D and 13G filings

Companies where Balyasny Asset Management LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

23 companies, largest stake first.

Companies where Balyasny Asset Management LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
XAIRBeyond Air, Inc.13G/A9.99%12.3M shares0.00 ppfrom 9.99%Feb 14, 20252 filingsMay 15, 2025SEC
LXEOLexeo Therapeutics, Inc.13G/A9.99%7.84M shares+0.30 ppfrom 9.69%Aug 14, 20255 filingsAug 14, 2026SEC
NERVMinerva Neurosciences, Inc.13G/A9.99%4.65M shares0.00 ppfrom 9.99%Feb 17, 20263 filingsAug 14, 2026SEC
NSRXNasus Pharma Ltd13G/A9.99%1.17M shares0.00 ppfrom 9.99%May 15, 20262 filingsAug 14, 2026SEC
CLRBCellectar Biosciences, Inc.13G9.99%798.4K sharesNewAug 14, 20261 filingAug 14, 2026SEC
IRLAIRulya Therapeutics Inc.13G9.99%97.7K sharesNewAug 14, 20261 filingAug 14, 2026SEC
SABSSAB Biotherapeutics, Inc.13G/A9.45%7.23M shares−0.54 ppfrom 9.99%May 15, 20262 filingsAug 14, 2026SEC
KRSAKorsana Biosciences, Inc.13G7.33%317.5K sharesNewAug 14, 20261 filingAug 14, 2026SEC
Korro Bio Ops, Inc.Common Stock, par value $0.001 per share13G7.21%1.04M sharesNewMay 15, 20261 filingMay 15, 2026SEC
CTNMContineum Therapeutics, Inc.13G/A7.14%2.34M shares−0.26 ppfrom 7.40%Feb 17, 20263 filingsAug 14, 2026SEC
HLXCHelix Acquisition Corp. III13G/A6.97%1.24M shares0.00 ppfrom 6.97%May 15, 20262 filingsAug 14, 2026SEC
IRDOpus Genetics, Inc.13G/A6.64%5.48M shares−0.54 ppfrom 7.18%Feb 17, 20263 filingsAug 14, 2026SEC
KRROKorro Bio, Inc.13G/A6.60%951.8K shares–Aug 14, 20261 filingAug 14, 2026SEC
TXNMTXNM Energy Inc13G/A6.43%7.11M shares−0.12 ppfrom 6.55%May 15, 20262 filingsAug 14, 2026SEC
RACCResearch Alliance Corp III13G6.43%500.0K sharesNewAug 14, 20261 filingAug 14, 2026SEC
SKYTSkyWater Technology, LLC13G6.35%3.12M sharesNewAug 14, 20261 filingAug 14, 2026SEC
JATTJATT II Acquisition Corp.13G6.23%500.0K sharesNewAug 14, 20261 filingAug 14, 2026SEC
CBIOCrescent Biopharma, Inc.13G/A6.03%1.66M shares+0.55 ppfrom 5.48%May 15, 20262 filingsAug 14, 2026SEC
SGMTSagimet Biosciences Inc.13G5.93%3.63M sharesNewAug 14, 20261 filingAug 14, 2026SEC
SPRSpirit AeroSystems Holdings, Inc.13G/A5.54%6.51M shares0.00 ppfrom 5.54%Aug 14, 20252 filingsNov 14, 2025SEC
XAIRBeyond Air, Inc.13G/A5.30%763.3K shares−1.95 ppfrom 7.25%Aug 14, 20255 filingsAug 14, 2026SEC
EHABEnhabit, Inc.13G/A5.22%2.65M shares–May 15, 20261 filingMay 15, 2026SEC
NGNENeurogene Inc.13G5.18%818.7K sharesNewAug 14, 20261 filingAug 14, 2026SEC

Latest filings

132 filings on file made by Balyasny Asset Management LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Balyasny Asset Management LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
XAIRBeyond Air, Inc.Aug 14, 20266:10 AM ET13G/A5.30%763.3K shares−1.95 ppfrom 7.25%Jun 30, 2026SEC
TXNMTXNM Energy IncAug 14, 20266:10 AM ET13G/A6.43%7.11M shares−0.12 ppfrom 6.55%Jun 30, 2026SEC
TALKTalkspace, Inc.Aug 14, 20266:09 AM ET13G/A4.09%6.86M shares−1.22 ppfrom 5.31%Below 5%Jun 30, 2026SEC
SKYTSkyWater Technology, LLCAug 14, 20266:09 AM ET13G6.35%3.12M sharesNewJun 30, 2026SEC
SGMTSagimet Biosciences Inc.Aug 14, 20266:09 AM ET13G5.93%3.63M sharesNewJun 30, 2026SEC
SABSSAB Biotherapeutics, Inc.Aug 14, 20266:08 AM ET13G/A9.45%7.23M shares−0.54 ppfrom 9.99%Jun 30, 2026SEC
RZLTRezolute, Inc.Aug 14, 20266:08 AM ET13G/A4.84%4.66M shares−0.44 ppfrom 5.28%Below 5%Jun 30, 2026SEC
RLYBRallybio CorpAug 14, 20266:08 AM ET13G/A0.00%0 shares−7.12 ppfrom 7.12%Below 5%Jun 30, 2026SEC
RACCResearch Alliance Corp IIIAug 14, 20266:07 AM ET13G6.43%500.0K sharesNewJun 30, 2026SEC
IRLAIRulya Therapeutics Inc.Aug 14, 20266:07 AM ET13G9.99%97.7K sharesNewJun 30, 2026SEC
OVIDOvid Therapeutics Inc.Aug 14, 20266:06 AM ET13G/A4.99%9.31M shares−0.34 ppfrom 5.33%Below 5%Jun 30, 2026SEC
NSRXNasus Pharma LtdAug 14, 20266:06 AM ET13G/A9.99%1.17M shares0.00 ppfrom 9.99%Jun 30, 2026SEC
NGNENeurogene Inc.Aug 14, 20266:05 AM ET13G5.18%818.7K sharesNewJun 30, 2026SEC
NERVMinerva Neurosciences, Inc.Aug 14, 20266:05 AM ET13G/A9.99%4.65M shares0.00 ppfrom 9.99%Jun 30, 2026SEC
LXEOLexeo Therapeutics, Inc.Aug 14, 20266:04 AM ET13G/A9.99%7.84M shares+0.30 ppfrom 9.69%Jun 30, 2026SEC
KRROKorro Bio, Inc.Aug 14, 20266:04 AM ET13G/A6.60%951.8K shares–Jun 30, 2026SEC
JATTJATT II Acquisition Corp.Aug 14, 20266:04 AM ET13G6.23%500.0K sharesNewJun 30, 2026SEC
IRDOpus Genetics, Inc.Aug 14, 20266:03 AM ET13G/A6.64%5.48M shares−0.54 ppfrom 7.18%Jun 30, 2026SEC
HLXCHelix Acquisition Corp. IIIAug 14, 20266:03 AM ET13G/A6.97%1.24M shares0.00 ppfrom 6.97%Jun 30, 2026SEC
KRSAKorsana Biosciences, Inc.Aug 14, 20266:02 AM ET13G7.33%317.5K sharesNewJun 30, 2026SEC